(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 December 2004 (09.12.2004)

PCT

(10) International Publication Number
WO 2004/105763 A2

(51) International Patent Classification[7]: A61K 31/506, 31/498, 31/517, 31/404, 31/42, 31/437, 31/47, 31/519, 38/12, 38/19, A61P 3/10

(21) International Application Number:
PCT/EP2004/005679

(22) International Filing Date: 26 May 2004 (26.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0312086.2	27 May 2003 (27.05.2003)	GB
0402682.9	6 February 2004 (06.02.2004)	GB

(71) Applicants and
(72) Inventors: **HÄGERKVIST, Robert, Per** [SE/SE]; Höganäsgatan 7B, S-753 30 Uppsala (SE). **WELSH, Nils, Richard** [US/SE]; Luthagsesplanaden 14, S-752 25 Uppsala (SE).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/105763 A2

(54) Title: USE OF A C-ABL-, PDGF-R-, OR C-KIT- TYROSINE KINASE INHIBITOR IN THE TREATMENT OF DIABETES

(57) Abstract: The invention relates to the use of a c-Abl-. PDGF-R-, or c-kit- tyrosine kinase inhibitor, e.g. 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of diabetes, e.g. type I diabetes, type II diabetes.